Topic

All

2
Feb
2023

When Life-Saving Medicines Are Ammunition in a Trade War

In early January, I held a telemedicine visit with a patient who reported a positive at-home COVID test and mild shortness of breath. During the visit, I looked through her health conditions and medications and decided that it was appropriate to prescribe Paxlovid. Later that day, she received the prescription from her local pharmacy, free of charge. Afterwards, I called...
Read More
1
Feb
2023

A Biotech Journalism Outlet Built to Last: Rick Berke on The Long Run

Today’s guest on The Long Run is Rick Berke. Rick is the co-founder and executive editor of STAT. Just about everyone who listens to The Long Run probably already reads STAT. If you don’t, you should. It’s become a go-to publication for breaking news, features, and in-depth investigative reporting across the world of biotech and healthcare. John Henry, the billionaire...
Read More
30
Jan
2023

Generative AI: No Humbug

In 1845, dentist Horace Wells stood before Harvard medical students and faculty, eager to demonstrate the utility of nitrous oxide – laughing gas – as a general anesthetic.  Wells tried it out on a patient who needed  a tooth extraction. The dose, it turned out, wasn’t enough. The patient screamed in agony.  As described by Paul Offit in You Bet...
Read More
24
Jan
2023

Biotech Needs to Get Back to Work in Person. Now.

Companies at the frontiers of science and medicine, developing new therapies for patients, are working on one of the most challenging endeavors known to humanity. Most would agree it’s more difficult than putting a man on the moon. The pandemic created a dramatic disruption to our globally networked economy. It will have far-ranging and long-lasting repercussions. It started with quarantine....
Read More
19
Jan
2023

From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run

Today’s guest on The Long Run is Jeb Keiper. Jeb is the CEO of Boston-based Nimbus Therapeutics. Nimbus made news in December 2022 when it sold its experimental Tyk2 inhibitor to Takeda Pharmaceuticals for $4 billion upfront and $2 billion in potential milestones. The drug’s value skyrocketed when it hit the primary endpoint of a Phase 2b clinical trial for...
Read More
19
Dec
2022

A New Way to Treat Depression: Barry Greene on The Long Run

Today’s guest on The Long Run is Barry Greene. Barry is the CEO of Cambridge, Mass.-based Sage Therapeutics. Sage is developing a new medicine for the treatment of major depressive disorder and postpartum depression. Sage, and its partner, Biogen, recently completed a New Drug Application to the FDA for permission to start marketing zuranolone. The drug is a once-daily oral...
Read More
14
Dec
2022

Reprofiling ‘Drug Repurposing’

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.